Literature DB >> 30104279

In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.

G Xue1,2, D M Crabb3, L Xiao4, Y Liu5,6, K B Waites7.   

Abstract

Levonadifloxacin (WCK 771) was evaluated against 68 type strains and clinical isolates of Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma spp. in comparison with moxifloxacin, levofloxacin, tetracycline, and azithromycin or clindamycin. Levonadifloxacin MICs were ≤0.5 μg/ml for M. genitalium MIC90s were 1 μg/ml for M. hominis, 0.125 μg/ml for M. pneumoniae, and 2 μg/ml for Ureaplasma spp. Levonadifloxacin merits further study for treating infections caused by these organisms.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Mycoplasma; Ureaplasma; WCK 771; antimicrobial resistance; levonadifloxacin; quinolone

Mesh：

Substances：

Year:  2018        PMID： 30104279      PMCID： PMC6201079          DOI： 10.1128/AAC.01348-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.

Authors:  Sachin S Bhagwat; Pamela McGhee; Klaudia Kosowska-Shick; Mahesh V Patel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

Review 2.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

Review 3.  Mycoplasma genitalium: from Chrysalis to multicolored butterfly.

Authors:  David Taylor-Robinson; Jørgen Skov Jensen
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

4.  In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy; Jorgen S Jensen; Yang Liu; Susanne Paukner
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.

Authors:  M H Gotfried; L H Danziger; K A Rodvold
Journal:  Chest       Date:  2001-04       Impact factor: 9.410

6.  Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Ravindra Yeole; Anasuya Patel; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

7.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Authors:  Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney Braman; Chistina Sutherland; David P Nicolau
Journal:  Chest       Date:  2004-03       Impact factor: 9.410
  8 in total
  5 in total

1.  In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae.

Authors:  Stephan Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

3.  Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model.

Authors:  Anasuya Patel; Ganesh V Sangle; Jinal Trivedi; Sushant A Shengule; Deepak Thorve; Mohan Patil; Nitin J Deshmukh; Bhushan Choudhari; Avinash Karade; Sangita Gupta; Sachin Bhagwat; Mahesh Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 4.  Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.

Authors:  Sachin S Bhagwat; Manohar Nandanwar; Atul Kansagara; Anusuya Patel; Swapna Takalkar; Rajesh Chavan; Hariharan Periasamy; Ravindra Yeole; Prasad K Deshpande; Satish Bhavsar; Ashima Bhatia; Jaishid Ahdal; Rishi Jain; Mahesh Patel
Journal:  Drug Des Devel Ther       Date:  2019-12-24       Impact factor: 4.162

Review 5.  Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies.

Authors:  Sandeep Nayar; Ashfaq Hasan; Pradyut Waghray; Srinivasan Ramananthan; Jaishid Ahdal; Rishi Jain
Journal:  Lung India       Date:  2019 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.